Cogentin (benztropine) does not treat tardive dyskinesia and can actually make it worse. Despite this, benztropine is still sometimes prescribed to people who have tardive dyskinesia, usually because the condition has been confused with a different movement disorder that benztropine does help. The distinction matters because the wrong treatment can deepen the problem, and effective options for tardive dyskinesia now exist.
Why Cogentin Gets Prescribed for the Wrong Movement Disorder
Benztropine is an anticholinergic medication. It works well for drug-induced parkinsonism, a condition where antipsychotic medications cause stiffness, tremor, and slow movement. Drug-induced parkinsonism and tardive dyskinesia can both emerge from the same antipsychotic medications, but they are fundamentally different problems with opposite treatment needs. Drug-induced parkinsonism involves too little dopamine activity, and anticholinergics help restore balance. Tardive dyskinesia involves excessive dopamine receptor sensitivity, and anticholinergics push things further in the wrong direction.1PubMed Central. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management
The confusion happens because both conditions can appear in the same patient, sometimes simultaneously. A person on an antipsychotic might develop stiffness in their limbs and involuntary tongue or jaw movements at the same time. If a clinician focuses on the stiffness and prescribes benztropine, the parkinsonism symptoms improve, which seems like a win. But the involuntary movements of tardive dyskinesia may quietly worsen, or they may be temporarily masked in a way that delays proper diagnosis.
How Benztropine Can Worsen Tardive Dyskinesia
A systematic review and meta-analysis of treatments for tardive dyskinesia found that anticholinergic agents produced almost no clinically relevant improvement and in some cases had a detrimental effect.2PubMed Central. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials This is consistent with the broader understanding that anticholinergics work against the neurochemistry of tardive dyskinesia rather than with it.
Animal research has shed light on why. In a study examining chronic benztropine and haloperidol administration, researchers found that benztropine given alone produced dopamine hypersensitivity, which is one of the key mechanisms thought to drive tardive dyskinesia. When haloperidol and benztropine were given together, this hypersensitivity was attenuated, but when benztropine was given on its own, it produced the same kind of sensitization that chronic antipsychotic use does. The researchers noted that benztropine’s ability to block dopamine reuptake, rather than just its anticholinergic properties, may explain this effect.3Psychopharmacology. Chronic benztropine and haloperidol administration induce behaviorally equivalent pharmacological hypersensitivities separately but not in combination In other words, benztropine is not simply a neutral add-on; it has its own potential to alter dopamine systems in ways that promote dyskinesia.
The Masking Problem and Withdrawal Dyskinesia
One of the more insidious aspects of benztropine use in people at risk for tardive dyskinesia is masking. Because benztropine relieves some types of movement symptoms, it can cover up emerging tardive dyskinesia. The person and their clinician may not realize the dyskinesia is developing until benztropine is stopped, at which point the movements appear suddenly and can be severe.
A published case report described a 31-year-old woman who developed acute-onset dyskinesia after benztropine was withdrawn.4PubMed Central. Withdrawal-Emergent Dyskinesia Related to Benztropine: A Case Report This kind of withdrawal-emergent dyskinesia can be alarming for both the patient and the treatment team, and it complicates clinical decision-making. Was the dyskinesia there all along, hidden by the anticholinergic? Or did stopping the benztropine trigger a new problem? These questions are hard to untangle in real time, which is why many guidelines now recommend against routine long-term benztropine prescribing alongside antipsychotics.
Anticholinergic Treatment as a Risk Factor for Developing Tardive Dyskinesia
Beyond failing to treat tardive dyskinesia, there is evidence that anticholinergic co-treatment may actually increase the risk of developing it in the first place. A review of clinical risk factors for tardive dyskinesia identified anticholinergic co-treatment as a modifiable treatment-related risk factor, alongside higher antipsychotic doses, early parkinsonian side effects, and akathisia.5PubMed. Clinical risk factors for the development of tardive dyskinesia
The word “modifiable” is worth pausing on. Many risk factors for tardive dyskinesia cannot be changed: older age, female sex, longer illness duration, certain genetic variations in dopamine-related genes. But anticholinergic co-treatment is something prescribers can control. Minimizing or avoiding benztropine when it is not strictly necessary may reduce the chance that tardive dyskinesia develops at all. Additional modifiable risk factors identified by the same review include diabetes, smoking, and substance use, as well as the choice of antipsychotic (older first-generation drugs carry higher risk than most newer second-generation ones).6PubMed. Clinical risk factors for the development of tardive dyskinesia
Advancing age appears to be the strongest single risk factor. A separate study that assessed risk factors for tardive dyskinesia found that onset of psychiatric illness at or after age 35 and first use of antipsychotics at or after 35 were significantly associated with developing the condition.7PubMed Central. Assesment of Risk Factors for Tardive Dyskinesia For older patients already at elevated risk, adding an anticholinergic that independently contributes to dopamine system changes is a particularly poor trade-off.
The Cognitive Cost of Benztropine
Even when benztropine is used appropriately for drug-induced parkinsonism, it comes with a significant side-effect burden that deserves more attention than it usually gets. A controlled comparison of benztropine and amantadine found that benztropine at 4 mg per day impaired free recall and perception of time, while amantadine at 200 mg per day did not. Participants on benztropine also perceived their own memory as worse, and anticholinergic side effects like dry mouth and blurred vision were more prominent. The study concluded that anticholinergic agents can levy a considerable burden on memory and time perception.8PubMed. Anticholinergic effects on memory: benztropine versus amantadine
For people with schizophrenia or other serious mental illnesses, cognitive function is already compromised by the illness itself and often by the antipsychotics being taken. Adding a medication that further impairs memory creates a layered problem. Patients may have trouble with adherence, daily functioning, and social interactions, and the anticholinergic may be making all of those harder without anyone connecting the dots. This cognitive burden is one more reason clinicians have been rethinking the reflexive use of benztropine as a preventive add-on to antipsychotic prescriptions.
Efforts to Reduce Unnecessary Benztropine Prescribing
In psychiatric inpatient settings, benztropine has historically been prescribed on a standing schedule alongside antipsychotics, sometimes prophylactically before any movement side effects have appeared. A quality improvement initiative at an acute psychiatric facility targeted this practice and found meaningful results. Following the intervention, the median duration of benztropine use for any indication dropped from 14 days to 7.5 days, and the percentage of patients on scheduled benztropine fell from about two-thirds to roughly 30%.9Oxford Academic. Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative
Projects like this reflect a broader shift in psychiatric practice. The old habit of automatically pairing an anticholinergic with every antipsychotic prescription is giving way to a more targeted approach: use benztropine when acute extrapyramidal symptoms actually appear, use the lowest effective dose, and taper off as soon as possible. The goal is to manage genuine parkinsonism without creating the conditions for tardive dyskinesia or cognitive impairment down the road.
What Actually Treats Tardive Dyskinesia
The first step in managing tardive dyskinesia, when clinically feasible, is reducing or discontinuing the antipsychotic medication that caused it. For many people with serious mental illness, stopping antipsychotics entirely is not realistic because it risks disease relapse. In those cases, switching from an older first-generation antipsychotic to a second-generation drug with lower dopamine D2 receptor affinity can help reduce tardive dyskinesia symptoms.10PubMed Central. Treatment Recommendations for Tardive Dyskinesia Clozapine and quetiapine are the most commonly recommended options for this switch. A systematic review of clozapine’s role found evidence supporting its use for both reducing tardive dyskinesia risk and treating existing symptoms, though the authors noted that rigorous randomized trials are still needed to confirm existing recommendations.11PubMed. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review
The biggest development in tardive dyskinesia treatment in recent years has been the approval of VMAT2 inhibitors, specifically valbenazine and deutetrabenazine. These medications work by reducing the amount of dopamine packaged into vesicles for release, which dampens the excessive dopamine signaling that drives the involuntary movements. Unlike benztropine, VMAT2 inhibitors have been tested in randomized controlled trials specifically for tardive dyskinesia and have shown genuine, clinically meaningful reductions in symptom severity.12PubMed Central. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials For many patients, these drugs have transformed what was once considered an essentially untreatable condition into something manageable.
The practical challenge with VMAT2 inhibitors is cost and access. These are newer brand-name medications, and insurance coverage varies. Some patients and clinicians default to older, cheaper drugs like benztropine not because the evidence supports it, but because the alternatives feel out of reach. That economic reality does not change the clinical picture, but it helps explain why benztropine continues to show up in tardive dyskinesia treatment despite the evidence against it.
Where Anticholinergics Do Help in Tardive Syndromes
The word “tardive” covers a family of conditions, not just one. Tardive dyskinesia gets the most attention, but tardive dystonia and tardive akathisia are related but distinct problems, and they respond to treatment differently. Unlike tardive dyskinesia, tardive dystonia and, to a lesser extent, tardive akathisia can improve with higher doses of anticholinergic medication.13Pharmacopsychiatry. Tardive drug-induced extrapyramidal syndromes
Tardive dystonia involves sustained, often painful muscle contractions and abnormal postures, typically in the neck, trunk, or limbs. It differs from the repetitive tongue-chewing or lip-smacking movements that characterize classic tardive dyskinesia. For tardive dystonia, anticholinergics like benztropine sometimes offer real relief, and higher doses may be needed. This is one reason clinicians who are experienced with tardive syndromes take careful stock of which type of movement disorder a patient actually has before choosing treatment.
Tardive akathisia, a persistent and distressing inner restlessness, occupies a more ambiguous space. A small double-blind crossover study in five patients with tardive akathisia found that intravenous benztropine produced a marginally significant improvement in overall symptoms, while propranolol (a beta-blocker) produced a more clearly significant improvement. The study also noted a considerable placebo effect and marked variability in how patients responded.14Psychopharmacology. Intravenous benztropine and propranolol challenges in tardive akathisia The evidence here is thin, but it illustrates that different tardive conditions are not interchangeable. A treatment plan built around a careful distinction between tardive dyskinesia, tardive dystonia, and tardive akathisia will look quite different from one that lumps them all together under a single prescription.
Getting the Diagnosis Right
The whole question of whether to use Cogentin for a tardive movement disorder ultimately comes down to diagnosis. A person searching for information about this topic may be experiencing involuntary movements on an antipsychotic and wondering whether benztropine is the right response. The answer depends heavily on what kind of movements are happening.
If the movements are rhythmic, repetitive motions of the tongue, jaw, lips, or fingers that developed gradually after months or years of antipsychotic use, that pattern fits classic tardive dyskinesia. Benztropine is not only unhelpful here but may worsen the condition and is considered a risk factor for its development.15PubMed Central. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management If the problem is stiffness, tremor, and slowed movement, that is more consistent with drug-induced parkinsonism, and benztropine is a reasonable short-term option. If the issue is sustained twisting postures, tardive dystonia is a possibility, and anticholinergics may genuinely help. If the primary complaint is a relentless inner urge to move, tardive akathisia is worth considering, though beta-blockers tend to outperform anticholinergics for that condition.
What makes this complicated in practice is that multiple types of movement disorder can coexist in the same person. Someone might have both drug-induced parkinsonism and early tardive dyskinesia. Treating the parkinsonism with benztropine could mask or accelerate the dyskinesia. This is where experienced clinical judgment matters, and where patients benefit from being informed enough to ask questions about what specific type of movement disorder has been identified and why a particular medication was chosen.